Trial Profile
The aim of this study is to describe the characteristics and treatment patterns in patients with relapse remitting Multiple Sclerosis in Israel treated with Dimethyl Fumarate
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 May 2017
Price :
$35
*
At a glance
- Drugs Dimethyl fumarate (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 25 May 2017 New trial record
- 24 May 2017 Results presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research